Management of Severe Muscular Pain in Statin-Intolerant Patients

Immediate Management of Severe Muscle Symptoms

The American College of Cardiology recommends promptly discontinuing the statin and evaluating for rhabdomyolysis by measuring CK, creatinine, and performing urinalysis for myoglobinuria if severe symptoms are present 2, 3
Severe symptoms warrant immediate cessation without attempting rechallenge until the clinical picture is clarified 1
If CK is >10 times the upper limit of normal with muscle symptoms, discontinue immediately and evaluate for rhabdomyolysis 4

The American College of Cardiology suggests evaluating for hypothyroidism (measure TSH), vitamin D deficiency (measure 25-OH vitamin D levels), reduced renal or hepatic function, rheumatologic disorders, and drug interactions with CYP3A4 inhibitors before accepting that a patient is truly statin-intolerant 2, 3, 5
Recent strenuous exercise or physical work should also be considered as a potential cause of muscle symptoms 4

The American College of Cardiology recommends waiting 2-4 weeks for complete symptom resolution before any rechallenge 6
Trying pitavastatin first as the preferred alternative statin due to superior tolerability in patients with prior statin-induced myalgia is suggested 6
At least 2-3 different statins should be tried, preferably ones metabolized by different pathways, before declaring true statin intolerance 6

The American College of Cardiology recommends ezetimibe 10 mg daily as the preferred first-line non-statin therapy for patients who cannot tolerate any statin 6
PCSK9 inhibitors (evolocumab or alirocumab) should be considered if LDL-C goals cannot be achieved with ezetimibe alone 1, 6

The American College of Cardiology suggests monitoring muscle symptoms at 6-12 weeks after starting new therapy and at each follow-up visit 6, 4
Measuring CK levels whenever the patient reports muscle soreness, tenderness, or weakness on any lipid-lowering therapy is recommended 6, 4

The American College of Cardiology advises against permanently discontinuing lipid-lowering therapy without attempting non-statin alternatives, as statin-intolerant patients have higher cardiovascular event risk 1
Assuming true statin intolerance until at least 2-3 different statins have been tried at various doses should be avoided 6
The nocebo effect, which accounts for the majority of reported statin-related symptoms, should not be ignored 6